As such, in light of advances in our understanding of BRCA-related breast and ovarian cancers – and the opportunity to directly impact therapeutic decision-making in these women – the recommendations to include universal germline BRCA1/2 testing to all women diagnosed with non-mucinous ovarian carcinoma (4) and women with triple-negative breast cancer (16) are growing in strength (17–19). Here, BRCA1 is linked to ovarian cancer.